These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

158 related articles for article (PubMed ID: 7928318)

  • 1. Home administration of intramuscular DHE for the treatment of acute migraine headache.
    Weisz MA; el-Raheb M; Blumenthal HJ
    Headache; 1994 Jun; 34(6):371-3. PubMed ID: 7928318
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Double-blind, multicenter trial to compare the efficacy of intramuscular dihydroergotamine plus hydroxyzine versus intramuscular meperidine plus hydroxyzine for the emergency department treatment of acute migraine headache.
    Carleton SC; Shesser RF; Pietrzak MP; Chudnofsky CR; Starkman S; Morris DL; Johnson G; Rhee KJ; Barton CW; Chelly JE; Rosenberg J; Van Valen MK
    Ann Emerg Med; 1998 Aug; 32(2):129-38. PubMed ID: 9701293
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Clinical experience with patient administered subcutaneous dihydroergotamine mesylate in refractory headaches.
    Klapper JA; Stanton J
    Headache; 1992 Jan; 32(1):21-3. PubMed ID: 1372884
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Implementation of an Intravenous Dihydroergotamine Protocol for Refractory Migraine in Children.
    Theroux LM; Cappa R; Mendoza A; Mallawaarachchi I; Samanta D; Goodkin HP
    Headache; 2020 Sep; 60(8):1653-1663. PubMed ID: 32853454
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Comparison of intravenous valproate versus intramuscular dihydroergotamine and metoclopramide for acute treatment of migraine headache.
    Edwards KR; Norton J; Behnke M
    Headache; 2001; 41(10):976-80. PubMed ID: 11903525
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A double-blind study of subcutaneous dihydroergotamine vs subcutaneous sumatriptan in the treatment of acute migraine.
    Winner P; Ricalde O; Le Force B; Saper J; Margul B
    Arch Neurol; 1996 Feb; 53(2):180-4. PubMed ID: 8639069
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Effectiveness of subcutaneous dihydroergotamine by home injection for migraine.
    Becker WJ; Riess CM; Hoag J
    Headache; 1996 Mar; 36(3):144-8. PubMed ID: 8984085
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Dosing and administration of ergotamine tartrate and dihydroergotamine.
    Mathew NT
    Headache; 1997; 37 Suppl 1():S26-32. PubMed ID: 9009471
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Dihydroergotamine nasal spray for the acute treatment of migraine.
    Ziegler D; Ford R; Kriegler J; Gallagher RM; Peroutka S; Hammerstad J; Saper J; Hoffert M; Vogel B; Holtz N
    Neurology; 1994 Mar; 44(3 Pt 1):447-53. PubMed ID: 8145914
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A comparison of subcutaneous sumatriptan and dihydroergotamine nasal spray in the acute treatment of migraine.
    Touchon J; Bertin L; Pilgrim AJ; Ashford E; Bès A
    Neurology; 1996 Aug; 47(2):361-5. PubMed ID: 8757005
    [TBL] [Abstract][Full Text] [Related]  

  • 11. DHE in the pharmacotherapy of migraine: potential for a larger role.
    Saper JR; Silberstein S; Dodick D; Rapoport A
    Headache; 2006 Nov; 46 Suppl 4():S212-20. PubMed ID: 17078853
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Acute treatment of migraine with dihydroergotamine nasal spray. Dihydroergotamine Working Group.
    Gallagher RM
    Arch Neurol; 1996 Dec; 53(12):1285-91. PubMed ID: 8970458
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Exacerbation of headache during dihydroergotamine for chronic migraine does not alter outcome.
    Eller M; Gelfand AA; Riggins NY; Shiboski S; Schankin C; Goadsby PJ
    Neurology; 2016 Mar; 86(9):856-9. PubMed ID: 26843569
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A clinical comparison of sumatriptan nasal spray and dihydroergotamine nasal spray in the acute treatment of migraine.
    Boureau F; Kappos L; Schoenen J; Esperanca P; Ashford E
    Int J Clin Pract; 2000 Jun; 54(5):281-6. PubMed ID: 10954953
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Ketorolac versus DHE and metoclopramide in the treatment of migraine headaches.
    Klapper JA; Stanton JS
    Headache; 1991 Sep; 31(8):523-4. PubMed ID: 1960056
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Dihydroergotamine nasal spray in the treatment of acute migraine.
    Treves TA; Kuritzky A; Hering R; Korczyn AD
    Headache; 1998 Sep; 38(8):614-7. PubMed ID: 11398305
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Repetitive dihydroergotamine nasal spray for treatment of refractory headaches: an open-label pilot study.
    Weintraub J
    Curr Med Res Opin; 2006 Oct; 22(10):2031-6. PubMed ID: 17022862
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Safety of domperidone in treating nausea associated with dihydroergotamine infusion and headache.
    Robbins NM; Ito H; Scheinman MM; Goadsby PJ
    Neurology; 2016 Dec; 87(24):2522-2526. PubMed ID: 27837002
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Efficacy of intravenous diphenhydramine versus intravenous DHE-45 in the treatment of severe migraine headache.
    Swidan SZ; Lake AE; Saper JR
    Curr Pain Headache Rep; 2005 Feb; 9(1):65-70. PubMed ID: 15625028
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A randomized, double blind, placebo-controlled study of MAP0004 in adult patients with migraine.
    Aurora SK; Rozen TD; Kori SH; Shrewsbury SB
    Headache; 2009 Jun; 49(6):826-37. PubMed ID: 19545249
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.